Bio-pharmaceutical company Ipsen is to invest a further €27m to upgrade manufacturing capability at its Blanchardstown site in Dublin, adding to its €25m investment earlier this year.

The investment will facilitate increased production of vital medical treatments, both for niche cancers and rare diseases. The earlier investment involved new equipment, enabling more efficient and sustainable production processes, and the upgraded facility recommenced manufacturing recently.

The company says the existing investment will “significantly increase Ipsen’s production of the active ingredient for one of its leading rare cancer treatments in 2022”.

Dublin head Tim Shanahan said: “Our dedicated employees here in Ireland are driven by a shared commitment to deliver life-changing care for patients with rare and underserved medical conditions.

“Our cumulative investment of €52m in Ipsen’s Irish manufacturing site this year will enable our team of 165 in Dublin to significantly scale its production of vital and innovative treatments as we move forward into 2022.

In Association with

“The Irish market plays a significant part in Ipsen’s international network and we are committed to continued improvement and growth of our activity here, with the constant goal of delivering better treatment for patients who deserve better care and quality of life.”

Ipsen is global mid-size bio-pharmaceutical company with a focus on transformative medicines in oncology, rare diseases and neuroscience. With total sales more than €2.5 billion in 2020, Ipsen sells more than 20 drugs and its R&D is focused on its innovative and differentiated technological platforms located at leading biotechnological and life sciences hubs  such as Paris-Saclay in France or Oxford University.

The company has been in Ireland for more than 30 years and produces the active ingredients for two of the company’s cancer treatments.